JOPIC
Journal of Pulmonology and Intensive Care

The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

eISSN: 2980-0803
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Frightening symptom hemoptysis: Analysis of etiology, mortality, and treatment outcomes in a large cohort from the chest disease center in Turkiye
Abstract
Aims: Hemoptysis can indicate serious, potentially life-threatening conditions. The etiology varies by region and can include tuberculosis (TB) in developing countries and malignancies in developed regions.
Methods: This retrospective cohort study reviewed medical records of 400 hospitalized hemoptysis patients between June 2012 and March 2016. Data collected included patient demographics, comorbidities, hemoptysis volume, diagnostic tests, treatments, and outcomes. Survival rates and readmissions were tracked for 2-6 years post-discharge.
Results: Of the 400 patients, 88 (22%) were female and 312 (78%) were male. The leading causes of hemoptysis were bronchiectasis (14%), sequela of tuberculosis (TB sequelae; 19%), and malignancy (22.8%). The most common causes in male patients were lung cancer (27.2%) and TB sequelae (21.8%). Bronchiectasis accounted for 28.4% of cases in female patients, followed by drug-induced hemoptysis at 14.8%. The in-hospital mortality rate was 1% (n = 4), with severe hemoptysis present in all four patients who died during admission for hemoptysis. The 2–6-year survival rate was 70.8% for women and 56.1% for men (p = 0.005). The factors found to significantly worsen mortality risk were lung malignancy, age >65, diabetes, and chronic obstructive pulmonary disease (COPD).
Conclusion: Overall, lung cancer was found to be the leading cause of hemoptysis, with bronchiectasis being the leading cause in female patients and malignancy in male patients. Close monitoring of male patients is crucial due to higher mortality risk. Careful assessment of patients with hemoptysis having comorbidities such as diabetes and COPD is required due to the reduced survival rates associated with these conditions. Early detection and intervention for lung cancer is essential to optimize the prognosis of affected individuals.

Keywords : Hemoptysis, malignancy, survival rate

Download Article


1. Kathuria H, Hollingsworth HM, Vilvendhan R, Reardon C.Management of life-threatening hemoptysis. J Intens Care. 2020;5(8):23.
2. Mondoni M, Carlucci P, Job S, et al. Observational, multicenterstudy on the epidemiology of hemoptysis. Int J Cardiovasc Imaging.2018;51(1):1701813.
3. Munjal SK, Natarajan S, Vinay V, Meenakshisundaram A. Clinicalprofile of patients hospitalized with hemoptysis. J Family Med PrimCare. 2022;11(11):7267-7271.
4. Quigley N, Gagnon S, Fortin M. A etiology, diagnosis and treatment ofmoderate-to-severe hemoptysis in a North American academic center.ERJ Open Res. 2020;6(4): 00204-2020.
5. Davoodi M, Kordi M, Gharibvand MM, Shoushtari MH, Borsi H,Bahadoram M. Hemoptysis: comparison of diagnostic accuracy ofmulti detector CT scan and bronchoscopy. Glob J Health Sci. 2015;7(3):373-377.
6. O’Gurek D, Choi HY. Hemoptysis: evaluation and management. Am FamPhysician. 2022;105(2):144-151.
7. Davidson K, Shojaee S. Managing massive hemoptysis. Chest. 2020;157(1):77-88.
8. Fartoukh M, Demoule A, Sanchez O, et al. Randomized trial of first-line bronchial artery embolization for non-severe hemoptysis of mildabundance. BMJ Open Respir Res. 2021;8(1):000949.
9. Avasarala SK, Rickman OB. Endobronchial therapies for diagnosis,staging, and treatment of lung cancer. Surg Clin North Am. 2022;102(3):393-412.
10. Özgül MA, Turna A, Yıldız P, et al. Risk factors and recurrence patterns in203 patients with hemoptysis. Tuberk Toraks. 2006;54(3):243-248.
11. Abal AT, Nair PC, Cherian J. Hemoptysis: a etiology, evaluation andoutcome: a prospective study in a third-world country. Respir Med. 2001;95(7):548-552.
12. Arooj P, Bredin E, Henry MT, et al. Bronchoscopy in the investigation ofoutpatients with hemoptysis at a lung cancer clinic. Respir Med. 2018;139(1):1-5.
13. Fidan A, Özdoğan S, Oruç O, Salepçi B, Öcal Z, Çağlayan B. Hemoptysis:a retrospective analysis of 108 cases. Respir Med. 2002;96(9):677-680.
14. Kumar A, Gupta AK, Gautam AK, et al. Not all hemoptysis is tuberculosisthink of other etiologies. A lesson from a chest clinic in a rural tertiary carecenter in central India. Int JEnviron Res Public Health. 2016;5(8):1662.
15. Yıldırım Z, Turkkani MH, Bozkurt H, et al. Effects of the healthtransformation programme on tuberculosis burden in Turkiye. RespirMed. 2013;107(12):2029-2037.
16. Bade BC, Dela Cruz CS. Lung Cancer 2020: epidemiology, etiology, andprevention. Clin Chest Med. 2020;41(1):1-24.
17. Vidaillac C, Yong VFL, Jaggi TK, Soh MM, Choti SH. Gender differencesin bronchiectasis: a real issue? Breathe. 2018;14(2):108-121.
18. Martinez García MA, Villa C, Dobarganes Y, et al. RIBRON: theSpanish online bronchiectasis registry. Characterization of the first 1912patients. RIBRON: el registro español informatizado de bronquiectasias.Caracterización de los primeros 1.912 pacientes. Archivos deBronconeumologia. 2021;57(1):28-35.
19. Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from householdair pollution in low and middle income countries. Lancet. 2014;2(10):823-860.
20. Park JE, Seo JA, Cha JG, et al. Association between high blood pressurein the emergency department and cryptogenic hemoptysis. J Clin Med.2022;11(18): 5302.
21. Ittrich H, Bockhorn M, Klose H, Simon MD. The diagnosis and treatmentof hemoptysis. Dtsch Arztebl Int. 2017;114(21):371-381.
22. Uzun O, Atasoy Y, Fındık S, Atıcı AG, Erkan L. A prospective evaluationof hemoptysis cases in a tertiary referral hospital. Clin Respir J. 2010;4(3):131-138.
23. Revel MP, Fournier LS, Hennebique AS, et al. Can CT replacebronchoscopy in the detection of the site and cause of bleeding in patientswith large or massive hemoptysis? Am J Roentgenol. 2002;179(5):1217-1224.
24. Ünsal E, Köksal D, Çimen F, et al. Analysis of patients with hemoptysis ina reference hospital for chest diseases. Tuberk Toraks. 2006;54(1):34-42.
25. Kinoshita T, Ohbe H, Matsui H, Fushimi K, Ogura H, Yasunaga H. Effectof tranexamic acid on mortality in patients with hemoptysis: a nationwidestudy. Crit Care. 2019;23(1):347.
26. Parrot A, Khalil A, Roques S, et al. Management of severe hemoptysis:experience in a specialized center. Rev Pneumol Clin . 2007;63(3):202-210.
27. Rémy J, Arnaud A, Fardou H, Giraud R, Voisin C. Treatment of hemoptysisby embolization of bronchial arteries. Radiolog. 1977;122(1):33-37.
28. Tayal M, Chauhan U, Sharma P, Dev R, Dua R, Kumar S. Bronchialartery embolization. What further we can offer? Wideochir Inne TechMaloinwazyjne. 2020;15(3):478-487.
29. Fruchter O, Schneer S, Rusanov V, Belenky A, Kramer MR. Bronchialartery embolization for massive hemoptysis: long-term follow-up. AsianCardiovasc Thorac Ann.2015;23(1):55-60.
30. Conlan AA, Hurwitz SS, Krige L, Nicolaou N, Pool R. Massive hemoptysis.Review of 123 cases. J Thorac Cardiovasc Surg. 1983;85(1):120-124.
31. Gourin A, Garzon AA. Operative treatment of massive hemoptysis. AnnThorac Surg. 1974;18(1):52-60.
32. Lim RK, Tremblay A, Lu S, Somayaji R. Evaluating hemoptysishospitalizations among patients with bronchiectasis in the United States:a population-based cohort study. BMC Pulm Med. 2021;21(1):392.
33. Lee BR, Yu JY, Ban HJ, et al. Analysis of patients with hemoptysis in atertiary referral hospital. Tuberc Respir Dis. 2012;73(2):107-114.
Article available in :
Volume 2, Issue 3, 2024
Page : 52-57
https://doi.org/10.51271/JOPIC-0036
Article Information
Received : 24 Tem 2024
Accepted : 07 Ağu 2024
Published : 15 Ağu 2024
Corresponding Author :

Nazan Beyhan: Department of Chest Diseases, Yedikule Pulmonary Diseases and Thoracic Surgery Training and Research Hospital, University of Health Sciences, İstanbul, Turkiye

[email protected]
Citation : Beyhan N, Kanmaz ZD, Aras G, Altın S, Tuncay E. Frightening symptom hemoptysis: analysis of etiology, mortality, and treatment outcomes in a large cohort from the chest disease center in Turkiye. J Pulmonol Intens Care. 2024;2(3):52-57.

Read: 89
Cited: 0
Download : 51
_Footer